Research Article

Clinical Evaluation And Treatment Outcomes In Non-Congenital Adrenal Hyperplasia: Insights From Primary And Central Adrenal Insufficiency Patients

Volume: 79 Number: 2 June 30, 2026
TR EN

Clinical Evaluation And Treatment Outcomes In Non-Congenital Adrenal Hyperplasia: Insights From Primary And Central Adrenal Insufficiency Patients

Abstract

Introduction: Adrenal insufficiency is a life-threatening endocrine disorder resulting from impaired cortisol production. It develops due to dysfunction of either the adrenal glands or the hypothalamic–pituitary axis. In children, the etiology and clinical manifestations vary widely, and delays in diagnosis and treatment can lead to significant morbidity. Objective: This study aimed to evaluate the clinical characteristics, etiological distribution, and treatment management of children diagnosed with primary adrenal insufficiency (PAI) and central adrenal insufficiency (CAI), excluding those with congenital adrenal hyperplasia (CAH). Methods: A retrospective analysis was conducted on 56 patients aged 0–18 years with PAI and CAI, followed by our Pediatric Endocrinology Department. Patients with CAH, secondary adrenal insufficiency due to steroid use, adrenal insufficiency from trauma, infections, or incomplete data were excluded. Data on clinical presentation, laboratory results, genetic assessments, and treatment were evaluated. Results: Of the 56 patients (28 males, 28 females), 75% (n=42) had CAI, and 25% (n=14) had PAI. Common etiologies in CAI included craniopharyngioma (n=21), while ACTH resistance (n=6) and APECED (n=5) were prevalent in PAI. The mean age at presentation was 6.99 ± 5.81 years, with PAI patients presenting at a younger median age (3.46 years) compared to CAI patients (6.83 years, p=0.11). Due to the predominance of craniopharyngioma patients, CAI patients had shorter stature (-1.03 ± 1.3 SD, p=0.01) and higher BMI SD scores (0.86 ± 1.72, p=0.007) than PAI patients. PAI patients exhibited higher baseline cortisol levels (7.22 ± 4.73 mcg/dL, p=0.01) and required higher initial hydrocortisone doses (20.88 ± 22.6 mg/m²/day) than CAI patients (11.49 ± 3.79 mg/m²/day, p=0.002). Conclusion: PAI patients presented younger and required higher hydrocortisone doses than CAI patients despite having higher baseline cortisol levels. Fatigue and hypoglycemia were frequent symptoms in PAI, while CAI presentations varied based on etiology.

Keywords

primary adrenal insufficiency, central adrenal insufficiency, pediatric endocrinology, cortisol, ACTH resistance, APECED, craniopharyngioma, hydrocortisone therapy

Ethical Statement

Written informed consent was obtained from the parent/legal guardian of participants prior to the study for the publication of details such as age, gender, illness. This study was reviewed and approved by Ankara University Ethic Committee and Ankara University Scientific Research Committee, approval number I04-151-22, decision date 16.03.2022.

Thanks

We thank all children and adolescents who participated in the study.

References

  1. Charmandari E, Nicolaides NC, Chrousos GP. Adrenal insufficiency. The Lancet. 2014;383(9935):2152-67.
  2. Bornstein SR. Predisposing factors for adrenal insufficiency. New England Journal of Medicine. 2009;360(22):2328-39.
  3. Guran T, Buonocore F, Saka N, Ozbek MN, Aycan Z, Bereket A, et al. Rare causes of primary adrenal insufficiency: genetic and clinical characterization of a large nationwide cohort. The Journal of Clinical Endocrinology & Metabolism. 2016;101(1):284-92.
  4. Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(2):364-89.
  5. Borchers J, Pukkala E, Mäkitie O, Laakso S. Epidemiology and causes of primary adrenal insufficiency in children: a population-based study. The Journal of Clinical Endocrinology & Metabolism. 2023;108(11):2879-85.
  6. Regal M, Páramo C, Sierra JM, García‐Mayor RV. Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clinical endocrinology. 2001;55(6):735-40.
  7. Tomlinson J, Holden N, Hills RK, Wheatley K, Clayton R, Bates A, et al. Association between premature mortality and hypopituitarism. The Lancet. 2001;357(9254):425-31.
  8. Hasenmajer V, Ferrigno R, Minnetti M, Pellegrini B, Isidori AM, Lenzi A, et al. Rare forms of genetic paediatric adrenal insufficiency: Excluding congenital adrenal hyperplasia. Reviews in Endocrine and Metabolic Disorders. 2023;24(2):345-63.
  9. Minnetti M, Caiulo S, Ferrigno R, Baldini‐Ferroli B, Bottaro G, Gianfrilli D, et al. Abnormal linear growth in paediatric adrenal diseases: Pathogenesis, prevalence and management. Clinical endocrinology. 2020;92(2):98-108.
  10. Berberoğlu M, Aycan Z, Ocal G, Begeot M, Naville D, Akar N, et al. Syndrome of congenital adrenocortical unresponsiveness to ACTH. Report of six patients. J Pediatr Endocrinol Metab. 2001;14(8):1113-8.
APA
Kizilcan Cetin, S., Şıklar, Z., Özsu, E., Aycan, Z., Ceran, A., Şenyazar, G., Erişen Karaca, S., Abseyi, S. N., Demirtas, S., & Berberoğlu, M. (2026). Clinical Evaluation And Treatment Outcomes In Non-Congenital Adrenal Hyperplasia: Insights From Primary And Central Adrenal Insufficiency Patients. Ankara Üniversitesi Tıp Fakültesi Mecmuası, 79(2), 142-149. https://doi.org/10.65092/autfm.1827711
AMA
1.Kizilcan Cetin S, Şıklar Z, Özsu E, et al. Clinical Evaluation And Treatment Outcomes In Non-Congenital Adrenal Hyperplasia: Insights From Primary And Central Adrenal Insufficiency Patients. Ankara Üniversitesi Tıp Fakültesi Mecmuası. 2026;79(2):142-149. doi:10.65092/autfm.1827711
Chicago
Kizilcan Cetin, Sirmen, Zeynep Şıklar, Elif Özsu, et al. 2026. “Clinical Evaluation And Treatment Outcomes In Non-Congenital Adrenal Hyperplasia: Insights From Primary And Central Adrenal Insufficiency Patients”. Ankara Üniversitesi Tıp Fakültesi Mecmuası 79 (2): 142-49. https://doi.org/10.65092/autfm.1827711.
EndNote
Kizilcan Cetin S, Şıklar Z, Özsu E, Aycan Z, Ceran A, Şenyazar G, Erişen Karaca S, Abseyi SN, Demirtas S, Berberoğlu M (June 1, 2026) Clinical Evaluation And Treatment Outcomes In Non-Congenital Adrenal Hyperplasia: Insights From Primary And Central Adrenal Insufficiency Patients. Ankara Üniversitesi Tıp Fakültesi Mecmuası 79 2 142–149.
IEEE
[1]S. Kizilcan Cetin et al., “Clinical Evaluation And Treatment Outcomes In Non-Congenital Adrenal Hyperplasia: Insights From Primary And Central Adrenal Insufficiency Patients”, Ankara Üniversitesi Tıp Fakültesi Mecmuası, vol. 79, no. 2, pp. 142–149, June 2026, doi: 10.65092/autfm.1827711.
ISNAD
Kizilcan Cetin, Sirmen - Şıklar, Zeynep - Özsu, Elif - Aycan, Zehra - Ceran, Aysegul - Şenyazar, Gizem - Erişen Karaca, Seda - Abseyi, Sema Nilay - Demirtas, Safak - Berberoğlu, Merih. “Clinical Evaluation And Treatment Outcomes In Non-Congenital Adrenal Hyperplasia: Insights From Primary And Central Adrenal Insufficiency Patients”. Ankara Üniversitesi Tıp Fakültesi Mecmuası 79/2 (June 1, 2026): 142-149. https://doi.org/10.65092/autfm.1827711.
JAMA
1.Kizilcan Cetin S, Şıklar Z, Özsu E, Aycan Z, Ceran A, Şenyazar G, Erişen Karaca S, Abseyi SN, Demirtas S, Berberoğlu M. Clinical Evaluation And Treatment Outcomes In Non-Congenital Adrenal Hyperplasia: Insights From Primary And Central Adrenal Insufficiency Patients. Ankara Üniversitesi Tıp Fakültesi Mecmuası. 2026;79:142–149.
MLA
Kizilcan Cetin, Sirmen, et al. “Clinical Evaluation And Treatment Outcomes In Non-Congenital Adrenal Hyperplasia: Insights From Primary And Central Adrenal Insufficiency Patients”. Ankara Üniversitesi Tıp Fakültesi Mecmuası, vol. 79, no. 2, June 2026, pp. 142-9, doi:10.65092/autfm.1827711.
Vancouver
1.Sirmen Kizilcan Cetin, Zeynep Şıklar, Elif Özsu, Zehra Aycan, Aysegul Ceran, Gizem Şenyazar, Seda Erişen Karaca, Sema Nilay Abseyi, Safak Demirtas, Merih Berberoğlu. Clinical Evaluation And Treatment Outcomes In Non-Congenital Adrenal Hyperplasia: Insights From Primary And Central Adrenal Insufficiency Patients. Ankara Üniversitesi Tıp Fakültesi Mecmuası. 2026 Jun. 1;79(2):142-9. doi:10.65092/autfm.1827711